Bimatoprost Patent Expiration
Bimatoprost is Used for reducing intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It was first introduced by Abbvie Inc
Bimatoprost Patents
Given below is the list of patents protecting Bimatoprost, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Durysta | US10398707 | Hypotensive lipid-containing biodegradable intraocular implants and related implants |
Apr 30, 2024
(Expired) | Abbvie |
| Durysta | US10441543 | Processes for making cyclic lipid implants for intraocular use | Dec 19, 2026 | Abbvie |
| Durysta | US7033605 | Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor |
Oct 20, 2020
(Expired) | Abbvie |
| Durysta | US7799336 | Hypotensive lipid-containing biodegradable intraocular implants and related methods | Apr 24, 2029 | Abbvie |
| Durysta | US8206737 | Hypotensive lipid-containing biodegradable intraocular implants and related methods | Apr 07, 2027 | Abbvie |
| Durysta | US8629185 | 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-N-ethyl-hept-5-enamide (bimatoprost) in crystalline form II, methods for preparation, and methods for use thereof | Jul 15, 2031 | Abbvie |
| Durysta | US8673341 | Intraocular pressure reduction with intracameral bimatoprost implants | Feb 19, 2025 | Abbvie |
| Durysta | US9149428 | Processes for making cyclic lipid implants for intraocular use | Dec 19, 2026 | Abbvie |
| Durysta | US9492316 | Prostamide-containing intraocular implants and methods of use thereof | Oct 31, 2034 | Abbvie |
| Durysta | US9980974 | Prostamide-containing intraocular implants and methods of use thereof | Oct 31, 2034 | Abbvie |
| Latisse | US6403649 | Non-acidic cyclopentane heptanoic acid,2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
Sep 21, 2012
(Expired) | Abbvie |
| Latisse | US7351404 | Method of enhancing hair growth |
May 25, 2024
(Expired) | Abbvie |
| Latisse | US7388029 | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
Jan 21, 2022
(Expired) | Abbvie |
| Latisse | US8017655 | Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
Nov 27, 2012
(Expired) | Abbvie |
| Latisse | US8038988 | Method of enhancing hair growth |
Aug 25, 2023
(Expired) | Abbvie |
| Latisse | US8101161 | Method of enhancing hair growth |
May 25, 2024
(Expired) | Abbvie |
| Latisse | US8263054 | Method of enhancing hair growth |
Aug 25, 2023
(Expired) | Abbvie |
| Latisse | US8541466 | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
Jan 31, 2021
(Expired) | Abbvie |
| Latisse | US8632760 | Method of enhancing hair growth |
Jan 15, 2023
(Expired) | Abbvie |
| Latisse | US8758733 | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
Jan 15, 2023
(Expired) | Abbvie |
| Latisse | US8906962 | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
Jan 31, 2021
(Expired) | Abbvie |
| Latisse | US8926953 | Method of enhancing hair growth |
Jan 15, 2023
(Expired) | Abbvie |
| Latisse | US8986715 | Method of enhancing hair growth |
Jan 15, 2023
(Expired) | Abbvie |
| Latisse | US9216183 | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
Jan 15, 2023
(Expired) | Abbvie |
| Latisse | US9226931 | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
Jan 15, 2023
(Expired) | Abbvie |
| Latisse | US9579270 | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
Jan 31, 2021
(Expired) | Abbvie |
| Lumigan | US5688819 | Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
Aug 19, 2014
(Expired) | Abbvie |
| Lumigan | US6403649 | Non-acidic cyclopentane heptanoic acid,2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
Sep 21, 2012
(Expired) | Abbvie |
| Lumigan | US7851504 | Enhanced bimatoprost ophthalmic solution | Jun 13, 2027 | Abbvie |
| Lumigan | US8017655 | Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
Nov 27, 2012
(Expired) | Abbvie |
| Lumigan | US8278353 | Enhanced bimatoprost ophthalmic solution | Mar 16, 2025 | Abbvie |
| Lumigan | US8299118 | Enhanced bimatoprost ophthalmic solution | Mar 16, 2025 | Abbvie |
| Lumigan | US8309605 | Enhanced bimatoprost ophthalmic solution | Mar 16, 2025 | Abbvie |
| Lumigan | US8338479 | Enhanced bimatoprost ophthalmic solution | Mar 16, 2025 | Abbvie |
| Lumigan | US8524777 | Enhanced bimatoprost ophthalmic solution | Mar 16, 2025 | Abbvie |
| Lumigan | US8586630 | Enhanced bimatoprost ophthalmic solution | Mar 16, 2025 | Abbvie |
| Lumigan | US8772338 | Enhanced bimatoprost ophthalmic solution | Mar 16, 2025 | Abbvie |
| Lumigan | US8933120 | Enhanced bimatoprost ophthalmic solution | Mar 16, 2025 | Abbvie |
| Lumigan | US8933127 | Enhanced bimatoprost ophthalmic solution | Mar 16, 2025 | Abbvie |
| Lumigan | US9155716 | Enhanced bimatoprost ophthalmic solution | Mar 16, 2025 | Abbvie |
| Lumigan | US9241918 | Enhanced bimatoprost ophthalmic solution | Mar 16, 2025 | Abbvie |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Bimatoprost Generics
Several generic applications have been filed for Bimatoprost. The first generic version for Bimatoprost was by Apotex Inc and was approved on Dec 1, 2014. And the latest generic version is by Eugia Pharma Specialities Ltd and was approved on Oct 6, 2022.
Given below is the list of companies who have filed for Bimatoprost generic.
1. GLAND PHARMA LTD
Gland Pharma Ltd has filed for 1 generic for Bimatoprost. Given below are the details of the strengths of this generic introduced by Gland Pharma Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.03% | solution/drops | Prescription | OPHTHALMIC | AT | Mar 22, 2019 |
2. HIKMA
Hikma Pharmaceuticals Usa Inc has filed for 1 generic for Bimatoprost. Given below are the details of the strengths of this generic introduced by Hikma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.03% | solution/drops | Discontinued | OPHTHALMIC | N/A | Nov 8, 2018 |
3. LUPIN LTD
Lupin Ltd has filed for 1 generic for Bimatoprost. Given below are the details of the strengths of this generic introduced by Lupin Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.03% | solution/drops | Prescription | OPHTHALMIC | AT | Feb 20, 2015 |
4. SANDOZ
Sandoz Inc has filed for 1 generic for Bimatoprost. Given below are the details of the strengths of this generic introduced by Sandoz.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.03% | solution/drops | Prescription | TOPICAL | AT | Apr 19, 2016 |
5. MICRO LABS
Micro Labs Ltd has filed for 1 generic for Bimatoprost. Given below are the details of the strengths of this generic introduced by Micro Labs.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.03% | solution/drops | Prescription | OPHTHALMIC | AT | Sep 8, 2020 |
6. SOMERSET THERAPS LLC
Somerset Therapeutics Llc has filed for 1 generic for Bimatoprost. Given below are the details of the strengths of this generic introduced by Somerset Theraps Llc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.03% | solution/drops | Prescription | OPHTHALMIC | AT | Jun 19, 2019 |
7. EUGIA PHARMA
Eugia Pharma Specialities Ltd has filed for 1 generic for Bimatoprost. Given below are the details of the strengths of this generic introduced by Eugia Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.03% | solution/drops | Prescription | OPHTHALMIC | AT | Oct 6, 2022 |
8. APOTEX
Apotex Inc has filed for 1 generic for Bimatoprost. Given below are the details of the strengths of this generic introduced by Apotex.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.03% | solution/drops | Prescription | OPHTHALMIC | AT | Jul 20, 2015 |
9. ALEMBIC
Alembic Pharmaceuticals Ltd has filed for 1 generic for Bimatoprost. Given below are the details of the strengths of this generic introduced by Alembic.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.03% | solution/drops | Prescription | TOPICAL | AT | Jan 21, 2020 |